Jordi Senserrich Velasco

I have been permorming research for almost 20 years. Since 2015 I have been a researcher at the IDIBELL/ICO, at the “Resistance to Anti-angiogenic Therapies and Tumour Malignization” group – L’Hospitalet de Llobregat (Barcelona, Spain). My research is mainly focused on the mechanisms responsible for increased malignancy of renal cell carcinomas (RCC) after anti-angiogenic treatments. I have been working with several patient-derived xenograft (PDX) mouse models from human RCC tumors derived from primary biopsies and cancer cell lines. Within this project I have acquired deep knowledge of tumor and associated stromal (importantly the endothelial compartment) cells behaviour and properties, and I have been able to characterize their phenotype and functionality using several in vitro and in vivo assays. Additionally, I have applied bioinformatics and omics approaches to determine factors and pathways responsible for the increased tumor invasiveness after anti-angiogenic therapies.